Your browser is no longer supported. Please, upgrade your browser.
Settings
PFE Pfizer Inc. daily Stock Chart
PFE [NYSE]
Pfizer Inc.
IndexDJIA S&P500 P/E27.84 EPS (ttm)1.22 Insider Own0.10% Shs Outstand6.16B Perf Week-0.73%
Market Cap209.21B Forward P/E12.94 EPS next Y2.63 Insider Trans-13.43% Shs Float6.06B Perf Month-1.11%
Income7.59B PEG3.56 EPS next Q0.62 Inst Own76.50% Short Float0.92% Perf Quarter15.09%
Sales50.99B P/S4.10 EPS this Y-21.50% Inst Trans1.47% Short Ratio1.48 Perf Half Y6.32%
Book/sh10.25 P/B3.31 EPS next Y7.63% ROA- Target Price38.71 Perf Year3.38%
Cash/sh3.16 P/C10.76 EPS next 5Y7.82% ROE- 52W Range27.71 - 35.50 Perf YTD7.25%
Dividend1.20 P/FCF- EPS past 5Y1.60% ROI8.00% 52W High-4.31% Beta0.85
Dividend %3.53% Quick Ratio1.20 Sales past 5Y-5.60% Gross Margin79.20% 52W Low22.58% ATR0.48
Employees97900 Current Ratio1.40 Sales Q/Q19.70% Oper. Margin- RSI (14)44.26 Volatility1.51% 1.33%
OptionableYes Debt/Eq0.62 EPS Q/Q28.90% Profit Margin- Rel Volume1.17 Prev Close34.59
ShortableYes LT Debt/Eq0.44 EarningsJul 26 BMO Payout- Avg Volume37.54M Price33.97
Recom2.20 SMA20-2.31% SMA500.61% SMA2006.72% Volume43,948,461 Change-1.79%
Jun-20-16Reiterated Jefferies Buy $42 → $40
May-12-16Initiated Berenberg Hold $38
May-04-16Reiterated UBS Buy $36 → $38
Apr-18-16Resumed Goldman Neutral $35
Apr-07-16Resumed Morgan Stanley Equal-Weight $35
Apr-07-16Resumed JP Morgan Overweight $38
Nov-25-15Upgrade Sun Trust Rbsn Humphrey Reduce → Neutral
Nov-03-15Reiterated Argus Buy $41 → $46
Oct-28-15Reiterated Deutsche Bank Buy $41 → $43
Oct-02-15Upgrade Morgan Stanley Equal-Weight → Overweight $35 → $38
Jul-29-15Reiterated Argus Buy $39 → $41
Jun-17-15Initiated Piper Jaffray Overweight
Apr-30-15Reiterated Argus Buy $36 → $39
Apr-29-15Downgrade Citigroup Buy → Neutral
Jan-28-15Reiterated Argus Buy $35 → $36
Dec-18-14Reiterated Deutsche Bank Buy $34 → $35
Jul-02-13Downgrade Standpoint Research Hold → Sell $24
Apr-15-13Reiterated Barclays Equal Weight $25 → $32
Jan-30-13Reiterated UBS Buy $29 → $31
Jan-30-13Reiterated Argus Buy $28 → $32
Jun-24-16 04:39PM  Brexit may make health care stocks a good defensive play at MarketWatch
01:21PM  Pfizer Completes Anacor Acquisition
11:08AM  Amgen Fits Into Pfizer's Restructuring Plans Perfectly
09:12AM  Allergan (AGN) Gets FDA Nod for Avycaz Label Expansion
09:00AM  Pfizer Completes Acquisition of Anacor Business Wire
Jun-23-16 08:37PM  Why Pfizer (PFE) is a Great Stock to Buy for the Long Run
05:56PM  Arkansas Supreme Court upholds lethal injection protocols Reuters
04:00PM  Pfizer Declares 30-Cent Third-Quarter 2016 Dividend Business Wire
08:51AM  Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data
08:05AM  20 Companies Buying Back the Most Stock in 2016 at 24/7 Wall St.
06:55AM  Five companies that could buy Ariad this year for as much as $2.9B at bizjournals.com
Jun-22-16 08:18PM  Jim Cramer's 'Mad Money' Recap: We Need More Mergers Right Now
02:58PM  U.S. companies spent record amount on buybacks over past 12 months at MarketWatch
09:40AM  This biotech start-up is betting your genes will yield the next wonder drug at CNBC
Jun-21-16 06:39PM  U.S. Market Indexes Gain as Investors Await UK Vote
04:01PM  The 4 Stocks That Lifted the Dow on Tuesday at 24/7 Wall St.
03:52PM  7 Profitable Medical Stocks Ranked as Buys Now
03:03PM  7 Pharmaceutical Stocks With Dividends Yielding More Than 3% at Motley Fool
10:00AM  Pfizer Invites Public To View And Listen To Webcast Of August 2 Conference Call With Analysts Business Wire
07:56AM  A Cheap Lunch From a Pharma Rep Can Influence Doctors Prescriptions at Fortune
07:14AM  Pfizer Stock Rises Despite Price Target Cut (PFE) at Investopedia
Jun-20-16 03:16PM  Rx pizza: 1 free meal can sway doctor prescribing
02:15PM  Street Talk: Corning, Yelp & more
11:21AM  Anthem & Cigna: Will Regulator Kill Another Big Merger? at Barrons.com
09:07AM  Pfizer (PFE) Stock Price Target Cut at Jefferies
08:55AM  Top Analyst Upgrades and Downgrades: Chesapeake Energy, Motorola Solutions, Pfizer, Spirit Air, Symantec, Under Armour, US Foods and More at 24/7 Wall St.
07:05AM  Early movers: AAPL, ANTM, FDML, YELP, PFE, SAVE & more at CNBC
04:46AM  Calls For Actions Grow Louder
Jun-19-16 07:23AM  3 Top Big Pharma Stocks to Buy Now at Motley Fool
Jun-18-16 11:00AM  Meet the Marijuana Industry Money-Man, Rob Hunt of Tuatara Capital
Jun-17-16 05:26PM  Stocks to give dad
04:01PM  The 4 Stocks That Tanked the Dow on Friday at 24/7 Wall St.
11:03AM  Paratek Reports Positive Phase III Data on Antibiotic Drug
10:49AM  Here's When You Should Buy Pfizer
07:00AM  Allergan Carves Middle Path In R&D Spending With 'Open Science'
Jun-16-16 07:46PM  Don't Make it Complicated, Own Drug Stocks
09:00AM  Help Pfizer Change The Future Of Healthy Aging Business Wire
08:30AM  Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts Business Wire
Jun-15-16 07:00PM  Cramer Remix: The Fed meetings over but caution ahead
05:26PM  Will A New Suitor For Anacor Emerge? at Forbes
05:19PM  Shire Buys Global Rights to Pfizer's Gastrointestinal Drug
04:01PM  The 4 Stocks That Weighed on the DJIA Wednesday at 24/7 Wall St.
03:00PM  Is Investment Banking Peaking? (PFE, AGN) at Investopedia
09:45AM  Infinity (INFI) at 52-Week Low on Disappointing Duvelisib Data
09:30AM  Zacks Industry Rank Analysis Highlights: Pfizer, Bristol-Myers Squibb and H Lundbeck
09:12AM  ICON and Pfizer Extend Ties, Sign New Agreement
Jun-14-16 06:18PM  Shire Gets Breakthrough Status for Rare Disease Candidates
04:44PM  U.S. regulator says too many drugmakers chasing same cancer strategy Reuters
01:37PM  Don't Make It Complicated, Own Drug Stocks
12:01PM  If I Plan On Investing My Social Security, What Dividend Stocks Can I Buy? at Motley Fool
09:55AM  Pfizer and Shire Move on IBD License Agreement
08:30AM  Superbug Hearing: Will Congress Pick Up Ali's Fight Against Sepsis? at Forbes
08:09AM  Shire buys bowel drug rights from Pfizer
08:08AM  Should Pfizer Buy This Beaten-Down Immuno-Oncology Company? at Motley Fool
07:25AM  Drugmaker Shire buys bowel drug rights from Pfizer
07:00AM  Shire to License PF-00547659 from Pfizer, Adding to Established and Leading Gastrointestinal Portfolio PR Newswire
Jun-13-16 11:58AM  Pfizer, Merck, Other Big Pharmas Likely to Acquire Marijuana-Based Drug Companies
10:21AM  Monday Headlines Being Dominated by Facebook, Pfizer, Symantec, More at Insider Monkey
10:00AM  Here's why all those big mergers are failing
09:56AM  Agios Reports Favorable Phase II PK Deficiency Study Data
09:53AM  Bull of the Day: Pfizer (PFE)
09:30AM  Pfizer, New York & Company, Wal-Mart Stores, Amazon and Alibaba Home highlighted as Zacks Bull and Bear of the Day
08:50AM  Pfizer Reveals Final Phase III Data on Inotuzumab Ozogamicin
07:30AM  [$$] Billions at Stake as Biotech-Copycat Startups Chase Pharma Giants at The Wall Street Journal
07:15AM  Spark Therapeutics Announces Updated Data from First Cohort in Hemophilia B Phase 1/2 Trial Demonstrating Consistent, Sustained Therapeutic Levels of Factor IX Activity GlobeNewswire
Jun-12-16 07:20AM  Dividend Stocks Retirees Can Buy at Motley Fool
05:15AM  Pfizer Announces Final Results from Inotuzumab Ozogamicin Pivotal Phase 3 Study in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia Business Wire
Jun-11-16 11:00AM  Merck, Pfizer Double Size of Diabetes Drug Study to Catch Rivals at Bloomberg
11:00AM  Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes Business Wire
Jun-10-16 10:19AM  [$$] Bristol-Myers, a Top Pharmaceuticals Pick at Barrons.com
10:00AM  ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV CNW Group
09:15AM  ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV PR Newswire
09:03AM  The C-Suite Speaks: Strategic Directions
08:53AM  Merck (MRK) to Acquire Afferent in Deal Worth Up To $1.25B
08:05AM  Major Pharma Has Short Sellers on the Run at 24/7 Wall St.
07:17AM  ICON Reveals Service Deal With Pfizer
07:00AM  U.S. regulator says too many drugmakers chasing same cancer strategy Reuters
Jun-09-16 06:22PM  Novartis (NVS) Announces Positive Results on Migraine Drug
02:00PM  Does your startup have what it takes for the new Alexandria LaunchLabs? at bizjournals.com
01:11PM  Here Is Why Big Pharma Stock Pfizer Is the Best Bet in the Sector
11:23AM  Theravance Biopharma Signs Licensing Deal with Takeda
09:50AM  Pfizer Inc. (PFE) Troxyca ER Receives FDA Panel Approval at Insider Monkey
09:07AM  What Caused Alexion Pharmaceuticals Fall?
09:03AM  Better Buy: GlaxoSmithKline vs. Pfizer at Motley Fool
07:30AM  Pro Golfer Jim Furyk Teams Up With Pfizer To Raise Awareness For Pneumococcal Pneumonia And The Importance Of Older Adult Vaccination Business Wire
Jun-08-16 07:15PM  Pfizer Announces FDA Advisory Committees Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval Business Wire
04:03PM  U.S. FDA panel backs approval of Pfizer's opioid painkiller Reuters
04:01PM  The 4 Stocks That Boosted the Dow Wednesday at 24/7 Wall St.
12:19PM  AbbVie Stock Downgraded As Worlds Best-Selling Drug Faces Rivals
12:06PM  What Are the Changes in AstraZenecas Profitability?
08:03AM  Pfizer To Present 23 Abstracts At European League Against Rheumatism Congress
07:34AM  Pfizer's Xeljanz Positive in Active Psoriatic Arthritis Study
07:26AM  Fresenius Is Leading Bidder for Pfizers Pumps Business at Bloomberg
07:01AM  Pfizer Research Advances Body Of Evidence For Tofacitinib Citrate (XELJANZ®) Providing Clinicians With Additional Information For The Treatment Of Moderate to Severe RA Business Wire
05:30AM  What To Look For In a Successful Money Manager Today: Character and Integrity
Jun-07-16 05:16PM  Expanding N.C. pharma gets FDA green light for generic of Pfizer drug at bizjournals.com
04:57PM  Merrimack Announces Positive Data on Oncology Candidate
03:46PM  Exelixis Up on Positive Kidney Cancer Data on Cabometyx
07:59AM  Another Strike Against TV Drug Ads: Opioid-Induced Constipation at Forbes
07:11AM  Pfizer reports positive results in trial of drug for adults with psoriatic arthritis at MarketWatch
Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. The company operates through Global Innovative Pharmaceutical (GIP); Global Vaccines, Oncology and Consumer Healthcare (VOC); and Global Established Pharmaceutical (GEP) segments. The GIP segment develops and commercializes medicines for various therapeutic areas, including inflammation/immunology, cardiovascular/metabolic, neuroscience/pain, and rare diseases. The VOC segment develops and commercializes vaccines, as well as products for oncology and consumer healthcare. It provides over-the-counter products comprising dietary supplements under the Centrum, Caltrate, and Emergen-C brands; pain management products under the Advil and ThermaCare brands; gastrointestinal products under the Nexium 24HR/Nexium Control and Preparation H brands; and respiratory and personal care products under the brand names of Robitussin, Advil Cold & Sinus, Advil Sinus Congestion Relief & Pain, Dimetapp, and ChapStick. The GEP segment offers products that have lost marketing exclusivity in various markets; and branded generics, generic sterile injectable products, biosimilars, infusion systems, and other products. The company serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as centers for disease control and prevention. It has licensing agreements with Cellectis SA and AstraZeneca PLC; and collaborative agreements with Eli Lilly & Company, OPKO Health, Inc., BioRap Technologies LTD., and Merck KGaA. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DAMELIO FRANK AExecutive Vice PresidentMay 26Option Exercise24.43100,0002,443,000472,994May 27 11:03 AM
DAMELIO FRANK AExecutive Vice PresidentMay 26Sale34.49100,0003,449,115372,994May 27 11:03 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Option Exercise25.8786,0002,224,820271,663May 26 10:07 AM
CANGIALOSI LORETTA VSr. Vice President, ControllerMay 24Sale33.9786,0002,921,147185,663May 26 10:07 AM
YOUNG JOHN DGroup PresidentMay 10Option Exercise25.8741,7001,078,779200,399May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Option Exercise24.43192,0004,690,560564,994May 11 06:04 PM
YOUNG JOHN DGroup PresidentMay 10Sale33.5341,7001,398,277158,699May 11 06:04 PM
DAMELIO FRANK AExecutive Vice PresidentMay 10Sale33.66192,0006,462,579372,994May 11 06:04 PM
READ IAN CChairman & CEOMay 09Option Exercise25.74275,0007,078,2501,471,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Option Exercise22.2823,884532,136199,735May 11 04:35 PM
HILL CHARLES HExecutive Vice PresidentMay 09Sale33.8429,6001,001,65160,828May 11 04:35 PM
SUSMAN SALLYExecutive Vice PresidentMay 09Sale33.7167,8842,288,669131,851May 11 04:35 PM
READ IAN CChairman & CEOMay 09Sale33.80275,0009,295,0391,196,738May 11 06:03 PM
SUSMAN SALLYExecutive Vice PresidentMay 05Option Exercise22.2856,0161,248,036231,867May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 05Sale33.7156,0161,888,144175,851May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Option Exercise22.2820,100447,828195,951May 06 09:51 AM
SUSMAN SALLYExecutive Vice PresidentMay 04Sale33.8720,100680,762175,851May 06 09:51 AM
DAMELIO FRANK AExecutive Vice PresidentMay 03Sale33.6587,0792,930,208372,994May 05 05:27 PM
Lewis-Hall Freda CExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541274,756Feb 26 03:05 PM
MADDALUNA ANTHONY JExecutive Vice PresidentFeb 24Option Exercise18.9062,4531,180,362140,772Feb 26 03:05 PM
OLSON LAURIE JExecutive Vice PresidentFeb 24Option Exercise18.9018,984358,79889,467Feb 26 03:05 PM
READ IAN CChairman & CEOFeb 24Option Exercise18.90584,11211,039,7172,030,151Feb 26 03:05 PM
SUSMAN SALLYExecutive Vice PresidentFeb 24Option Exercise18.90110,9812,097,541263,151Feb 26 03:05 PM
YOUNG JOHN DGroup PresidentFeb 24Option Exercise18.9052,570993,573188,679Feb 26 03:05 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerFeb 24Option Exercise18.9034,171645,832210,943Feb 26 03:05 PM
DAMELIO FRANK AExecutive Vice PresidentFeb 24Option Exercise18.90210,2803,974,292622,467Feb 26 03:05 PM
Dolsten MikaelPresident R&DFeb 24Option Exercise18.90210,2803,974,292577,902Feb 26 03:05 PM
HILL CHARLES HExecutive Vice PresidentFeb 24Option Exercise18.9078,8551,490,360149,135Feb 26 03:05 PM
JOHNSON RADY AExecutive Vice PresidentFeb 24Option Exercise18.9019,188362,65366,048Feb 26 03:05 PM
LANKLER DOUGLAS MExecutive Vice PresidentFeb 24Option Exercise18.9034,171645,832149,482Feb 26 03:05 PM
BOURLA ALBERTGroup PresidentFeb 24Option Exercise18.9030,666579,587144,675Feb 26 03:03 PM
BOURLA ALBERTGroup PresidentDec 15Option Exercise26.2030,000786,000140,560Dec 16 06:46 PM
YOUNG JOHN DGroup PresidentDec 14Option Exercise26.2031,500825,300163,999Dec 16 06:55 PM
PFIZER INC10% OwnerOct 06Buy7.00714,2854,999,9952,253,509Oct 07 05:42 PM
CANGIALOSI LORETTA VSr. Vice President, ControllerJul 30Sale35.6524,704880,646174,611Aug 03 07:24 AM